$OLMA News

JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate

Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Olema Pharma Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA In Patients With mCRPC

Olema Pharmaceuticals Reports Initial Clinical Data From The Phase 1 Study of OP-3136, A KAT6 Inhibitor, At 2026 ASCO Annual Meeting; OP-3136 Monotherapy Was Well-tolerated With No Dose-limiting Toxicities Observed And No Discontinuations Due To Treatment-related Adverse Events; OP-3136 Shows Evidence Of Anti-tumor Activity Across Multiple Solid Tumor Types

Olema: The Market Overreacted To Roche's SERD Failure

Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Olema Pharmaceuticals (NASDAQ:OLMA) Reports Narrower Q1 Loss, Eyes Fall Breast Cancer Data Readout

Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate

Olema Pharma To Present Phase 1 OP-3136 Data And Phase 3 OPERA-02 Trial Updates At ASCO 2026

Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study

Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study

Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $58

Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $27

Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $62